e-therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of e-therapeutics generated cash of -$7,544,000, which is less than the previous year. Cash used in financing activities reached the amount of $13,046,000 last year. Net change in cash is therefore $20,343,000.
Cash Flow
| 2010 | -1.77M | -101K | 4.35M |
|---|---|---|---|
| 2011 | -1.91M | -120K | 82K |
| 2012 | -3.23M | -7.91M | 16.38M |
| 2016 | -9.17M | 13.68M | 12K |
| 2018 | -4.40M | 7.01M | 12K |
| 2020 | -2.01M | -16K | -35K |
| 2021 | -3.34M | -71K | 12.59M |
| 2023 | -7.54M | 14.84M | 13.04M |
ETX.L Cash Flow Statement (2010 – 2022)
| 2022 | 2020 | 2019 | 2017 | 2015 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 11.34M | 3.84M | 5.90M | 4.47M | 1.82M | 927K | 2.88M | 409K |
Operating activities | ||||||||
Net income | -8.27M | -3.68M | -2.34M | -5.35M | -8.82M | -3.24M | -2.31M | -1.77M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||
Depreciation and amortization | 468K | 82K | 94K | 62K | 73K | 81K | 135K | 20K |
Stock-based compensation expense | 155K | 422K | 36K | 105K | 215K | 11K | 18K | 0 |
| Deferred income tax benefit | 155K | 422K | 36K | 105K | 215K | 11K | 18K | 0 |
| Changes in operating assets and liabilities: | ||||||||
Accounts receivable, net | -75K | -168K | 161K | 145K | 40K | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 198K | 189K | -500K | 0 | 23K | 0 | 0 | 0 |
Cash generated by operating activities | -7.54M | -3.34M | -2.01M | -4.40M | -9.17M | -3.23M | -1.91M | -1.77M |
Investing activities | ||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | -7.75M | 0 | 0 |
Investments In Property Plant And Equipment | -210K | -71K | -16K | -66K | -6K | -267K | -134K | -113K |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 14.84M | -71K | -16K | 7.01M | 13.68M | -7.91M | -120K | -101K |
Financing activities | ||||||||
Common Stock Issued | 13.43M | 12.64M | 11K | 12K | 12K | 17.68M | 82K | 3.31M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | -391K | -46K | -46K | 0 | 0 | -1.29M | 0 | 0 |
Cash used in financing activities | 13.04M | 12.59M | -35K | 12K | 12K | 16.38M | 82K | 4.35M |
Net Change In Cash | 20.34M | 9.18M | -2.06M | 2.62M | 4.52M | 5.22M | -1.95M | 2.47M |
Cash at end of period | 31.68M | 13.02M | 3.84M | 7.09M | 6.34M | 6.15M | 927K | 2.88M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |